Brookline Capital Management Estimates CRSP Q3 Earnings

Key Points

• Brookline Capital Management has increased its Q3 2025 earnings estimate for CRISPR Therapeutics to ($1.23) per share, up from the previous estimate of ($1.25).
• CRISPR Therapeutics reported earnings of ($1.29) per share for its latest quarter, surpassing analysts' expectations of ($1.47) by $0.18.
• Various analysts have varying ratings for CRISPR Therapeutics, with targets ranging from $42.00 to $105.00, reflecting a generally cautious outlook for the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Brookline Capital Management boosted their Q3 2025 earnings estimates for CRISPR Therapeutics in a research report issued to clients and investors on Monday, August 4th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($1.23) per share for the quarter, up from their previous estimate of ($1.25). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics' FY2025 earnings at ($5.34) EPS, FY2026 earnings at $2.75 EPS, FY2027 earnings at $4.92 EPS, FY2028 earnings at $9.57 EPS and FY2029 earnings at $44.54 EPS.

Several other equities research analysts have also recently commented on CRSP. The Goldman Sachs Group lowered their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Royal Bank Of Canada upped their target price on CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a research report on Tuesday. Chardan Capital reiterated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a report on Tuesday. JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Finally, Piper Sandler reiterated an "overweight" rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $71.60.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $56.34 on Thursday. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of -10.38 and a beta of 1.80. The business has a 50 day simple moving average of $50.83 and a 200 day simple moving average of $43.72. CRISPR Therapeutics has a 52 week low of $30.04 and a 52 week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The firm's quarterly revenue was up 72.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.49) EPS.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently modified their holdings of the business. IFP Advisors Inc lifted its holdings in shares of CRISPR Therapeutics by 24.6% during the 2nd quarter. IFP Advisors Inc now owns 916 shares of the company's stock valued at $45,000 after purchasing an additional 181 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of CRISPR Therapeutics by 1.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 22,066 shares of the company's stock worth $1,073,000 after purchasing an additional 243 shares during the last quarter. SFE Investment Counsel increased its position in shares of CRISPR Therapeutics by 5.8% during the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after purchasing an additional 355 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of CRISPR Therapeutics by 6.4% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,091 shares of the company's stock worth $296,000 after purchasing an additional 366 shares during the last quarter. Finally, Axxcess Wealth Management LLC increased its position in shares of CRISPR Therapeutics by 4.0% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,309 shares of the company's stock worth $351,000 after purchasing an additional 393 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the transaction, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Simeon George acquired 989,812 shares of the stock in a transaction that occurred on Wednesday, July 16th. The stock was purchased at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 4.30% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.